Schizophrenia News

Teva Pharmaceuticals recently announced a voluntary recall on one lot of 90-count, 3-mg bottles of paliperidone extended-release tablets to retail and consumers.

Nationwide study results indicated low social maturity, mental energy and emotional stability in late adolescence were associated with subsequent psychiatric disorders among men.

Analysis of 60 years of placebo-controlled antipsychotic drug trials indicated approximately twice as many individuals with acute schizophrenia improved with antipsychotics compared with placebo, but not many had a good response.

Recovery-oriented cognitive therapy improved functioning in schizophrenia, notably among individuals with higher chronic illness.

Long-acting injectable antipsychotic medications and clozapine were associated with highest rates of prevention of relapse in schizophrenia, according to recent findings.

The FDA today approved 2-month Aristada, an extended-release injectable suspension, to treat schizophrenia.

SAN DIEGO — Data showing long-term efficacy and pharmacokinetic profile of Ingrezza capsules, recently approved by the FDA for treatment of tardive dyskinesia, was presented at the American Psychiatric Association Annual Meeting.

SAN DIEGO — Psychiatrists for too long have had a “desire to not be aware of the problem” of tardive dyskinesia, according a psychiatrist presenting at an industry press conference.

SAN DIEGO — Findings presented here indicated that prescription of second-generation antipsychotics with lower metabolic risk have increased from 2006 to 2011, particularly for individuals with several metabolic disorders, but not those with cardiovascular disease.

SAN DIEGO — Timely follow-up with a physician reduced risk for early readmission among individuals with schizophrenia, particularly those with high-risk for readmission at discharge, according to data presented at the American Psychiatric Association Annual Meeting.